Targeted therapy and new anticancer drugs in advanced disease

Area of Science:

• Oncology
• Pharmacology
• Medical Genetics

Background:

• Lung cancer remains a leading cause of cancer-related mortality worldwide.
• Recent advancements in molecular biology have identified specific targets for therapeutic intervention.
• Personalized medicine approaches are transforming lung cancer management.

Purpose of the Study:

• To review the main categories of novel targeted therapy agents for lung cancer.
• To discuss the clinical evidence supporting the use of these targeted agents.
• To highlight the shift towards personalized treatment strategies in non-small cell lung cancer.

Main Methods:

• Literature review of targeted therapies in lung cancer.
• Analysis of clinical trial data for novel agents.
• Synthesis of evidence for different drug classes and targets.

Main Results:

• Targeted therapies have demonstrated significant improvements in clinical outcomes for specific patient subgroups.
• Key categories include inhibitors of EGFR, ALK, ROS1, BRAF, and immunotherapy checkpoint inhibitors.
• Personalized treatment selection based on molecular profiling is becoming standard practice.

Conclusions:

• Targeted therapies represent a major advancement in lung cancer treatment, especially for non-small cell lung cancer.
• Continued research is essential to identify new targets and overcome resistance mechanisms.
• The integration of targeted agents enhances personalized care and improves patient prognosis.